32
Participants
Start Date
October 31, 2003
Primary Completion Date
June 30, 2004
Study Completion Date
September 30, 2008
Capecitabine
Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
OSI-774
Given once daily
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
Roche Global Development
OTHER
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Dana-Farber Cancer Institute
OTHER